Do daily multivitamins slow biological aging?

Small but measurable changes in biological age markers

A large randomized trial tested whether a daily multivitamin affects molecular signs of aging. Over two years, participants who took a multivitamin showed modest slowing on epigenetic “clocks” — laboratory measures that infer biological age from DNA‑based markers — compared with those taking placebo.

The result is not a dramatic reversal of ageing, but it is notable for being observed in a randomized clinical trial. The slowing was larger in people whose epigenetic measures suggested they were already biologically older than their chronological age. Researchers emphasize the effect size was modest and limited to biomarkers rather than clinical outcomes such as disease incidence or lifespan.

What this implies

• Accessibility: Multivitamins are inexpensive and widely available, so even a modest biomarker effect could have broad public‑health relevance if it translates into real health benefits.
• Uncertainty about clinical impact: Slower epigenetic ageing does not automatically mean fewer diseases or longer healthy lives; longer follow‑up and trials focused on clinical endpoints are needed.
• Population differences: The benefit appeared greater in people with advanced biological ageing, suggesting targeted studies could clarify who might gain the most.

Next steps include confirming the finding in other cohorts, extending follow‑up to see if biomarker changes predict real health gains, and understanding which ingredients or combinations drive the effect. For now, daily multivitamins appear to change molecular aging signals modestly, but whether that shift improves long‑term health remains unanswered.